Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. AstraZeneca PLC
  6. News
  7. Summary
    AZN   GB0009895292


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

AstraZeneca : Madrid residents line up for AstraZeneca shot despite blood clot link

04/07/2021 | 01:29pm EDT

MADRID, April 7 (Reuters) - Madrid residents were broadly confident about AstraZeneca's coronavirus shot on Wednesday despite European and British regulators finding a potential link between the vaccine and rare brain blood clots.

"If you read any package leaflet for any medicine, there are always problems for a small number of people," said Pilar Garcia, waiting in line to receive an AstraZeneca shot outside Atletico Madrid's Wanda Metropolitano soccer stadium, which is being used as mass vaccination centre.

"I think this is the same thing."

The European Union's EMA medicines regulator said on Wednesday said it had reports of 169 brain clots after administering 34 million doses.

"Today has been a very distressing day because of all the news coming from the European Medicines Agency," said Madrid resident Carmen Ruiz, shortly after receiving an injection.

Despite referring to mixed messages from authorities as an "outrage" she decided to trust the EMA's advice that the benefits of the drug outweighed the risks.

Some countries are only using AstraZeneca on limited age groups and the EMA said European countries should make their own decisions about how to handle the risk, given infection rates and available alternatives.

Before the EMA announced its findings, authorities in the Central Spanish region of Castile and Leon suspended the shot, although the national government decided to carry on with it.

Spain's health minister is expected to announce new guidelines on the shot after a summit of European health chiefs, and to clarify rules for wearing masks on beaches.

The patchwork of national and regional rules governing the vaccine exasperated 63-year-old Felicidad Gutierrez.

"(They say) it's no good, in some places it has been suspended, but if we listened to everything they say we'd end up doing nothing," she told Reuters after leaving the stadium.

"I decided to come anyway." (Reporting by Guillermo Martinez and Elena Rodriguez; Writing by Nathan Allen; Editing by Alison Williams)

© Reuters 2021
All news about ASTRAZENECA PLC
08:15aCOVID-19 VACCINES AND RARE BLOOD CLO : Are Women at Greater Risk?
04/17ASTRAZENECA  : Canada has second case of rare blood clots after AstraZeneca vacc..
04/17ASTRAZENECA  : Canada has second case of rare blood clots after AstraZeneca COVI..
04/17U.S. PARENTS BEGIN TO ASK : Should my child get a COVID-19 shot?
04/17ASTRAZENECA  : Alberta confirms country's second blood clot after AstraZeneca va..
04/17ASTRAZENECA  : Covid-19 Vaccine - No Diagnosed Case of Blood Clots, No Death Rec..
04/17ASTRAZENECA  : Covid-19 - Nigeria Crosses 1 Million Vaccination Threshold
04/17Expat Americans Fly Home for Covid-19 Vaccination Shots
04/17MODERNA  : vaccine shipments to the UK delayed over supply chain concerns
04/16ASTRAZENECA  : Quebec to deploy sound trucks in Montreal to announce mobile vacc..
More news
Financials (USD)
Sales 2021 30 793 M - -
Net income 2021 5 064 M - -
Net Debt 2021 11 692 M - -
P/E ratio 2021 26,1x
Yield 2021 2,79%
Capitalization 134 B 134 B -
EV / Sales 2021 4,73x
EV / Sales 2022 4,09x
Nbr of Employees 76 100
Free-Float 95,8%
Duration : Period :
AstraZeneca PLC Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASTRAZENECA PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 25
Average target price 129,60 $
Last Close Price 102,07 $
Spread / Highest target 62,6%
Spread / Average Target 27,0%
Spread / Lowest Target -7,74%
EPS Revisions
Managers and Directors
Pascal Soriot Chief Executive Officer & Executive Director
Marc Pierre Jean Dunoyer Chief Financial Officer & Executive Director
Leif Valdemar Johansson Non-Executive Chairman
Menelas N. Pangalos EVP-Biopharmaceuticals Research & Development
Pam P. Cheng Executive VP-Operations & Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON3.09%427 130
ROCHE HOLDING AG0.06%289 376
PFIZER INC.2.15%215 150
NOVARTIS AG-3.32%198 528
MERCK & CO., INC.-5.29%196 100